GR76769B - - Google Patents

Info

Publication number
GR76769B
GR76769B GR69591A GR820169591A GR76769B GR 76769 B GR76769 B GR 76769B GR 69591 A GR69591 A GR 69591A GR 820169591 A GR820169591 A GR 820169591A GR 76769 B GR76769 B GR 76769B
Authority
GR
Greece
Prior art keywords
gene
allergen
vertebrate
pathogen
organism
Prior art date
Application number
GR69591A
Other languages
English (en)
Inventor
Roy Qurtiss Iii
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of GR76769B publication Critical patent/GR76769B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GR69591A 1981-10-22 1982-10-21 GR76769B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31403081A 1981-10-22 1981-10-22

Publications (1)

Publication Number Publication Date
GR76769B true GR76769B (el) 1984-09-03

Family

ID=23218251

Family Applications (1)

Application Number Title Priority Date Filing Date
GR69591A GR76769B (el) 1981-10-22 1982-10-21

Country Status (7)

Country Link
EP (1) EP0080806B1 (el)
JP (2) JPH0811735B2 (el)
AT (1) ATE44765T1 (el)
CA (1) CA1338705C (el)
DE (1) DE3279824D1 (el)
GR (1) GR76769B (el)
IE (1) IE55478B1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
IT1217303B (it) * 1984-02-01 1990-03-22 Enterovax Res Pty Ltd Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini
US5288617A (en) * 1984-10-31 1994-02-22 Commonwealth Scientific And Industrial Research Organization Method of producing an antigenic preparation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
EP0250614A1 (en) * 1986-06-23 1988-01-07 Serum Und Impfinstitut Und Institut Zur Erforschung Der Infektionskrankheiten Schweiz. DNA fragments encoding the chromosomal nucleotide sugar synthetases and glycosyl transferases
US5204097A (en) * 1986-07-06 1993-04-20 Yeda Research And Development Company Limited Shiga toxin B chain polypeptides and vaccine thereto
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
WO1989003427A1 (en) * 1987-10-07 1989-04-20 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
CA1339307C (en) * 1988-09-06 1997-08-19 Roy Curtiss, Iii Oral immunization by transgenic plants
DK0454735T3 (da) * 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
IL100010A (en) * 1990-11-09 1998-02-08 Univ Washington ALLENOMLAS non-violent strains that include a mutation in the TDC gene and immunogenic preparations that contain the above-mentioned non-violent strains of ALLENOMLAS
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
CA2154379A1 (en) * 1994-07-22 1996-01-23 Shyam S. Mohapatra Parietaria allergens
DE69635472T2 (de) 1995-07-03 2006-04-13 Akzo Nobel N.V. Impfstoff gegen Geflügelkokzidose
US6221364B1 (en) 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1057892A1 (en) * 1999-06-02 2000-12-06 Centrum voor Onderzoek in Diergeneeskunde en Agrochemie Attenuated mutant enteropathogenic E. coli (EPEC) strains, process for their production and their use
AU2001219510B2 (en) * 2000-04-06 2007-06-14 Allertein Therapeutics, Llc Microbial delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
CN1245960C (zh) * 2000-05-26 2006-03-22 高田宽治 具有3层结构的非口服用制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472624A (en) * 1974-09-02 1977-05-04 Canadian Patents Dev Enteric disease vaccine
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
DE2530275A1 (de) * 1975-07-07 1977-01-27 Max Planck Gesellschaft Salmonella-coli-hybride, verfahren zu deren herstellung und vermehrung und apathogener lebend-impfstoff gegen salmonellosen
DK493878A (da) * 1977-11-08 1979-05-09 Genentech Inc Fremgangsmaade og middel til mikrobiel polypeptid-udrykning
US4133875A (en) * 1978-02-23 1979-01-09 Forsyth Dental Infirmary For Children Method of controlling dental caries with streptococcus mutans mutant strains
GB2033223B (en) * 1978-09-01 1983-09-14 Secr Social Service Brit Antigen fromstreptococcus mutans for protection against dental caries
FR2442271A1 (fr) * 1978-11-27 1980-06-20 Pasteur Institut Vecteur permettant l'insertion d'un gene procaryote ou eucaryote, et l'excretion de la proteine exprimee
DE2942780A1 (de) * 1979-10-23 1981-05-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
GB2084583B (en) * 1980-09-18 1984-12-19 Nat Res Dev Synthetic dna and process therefor
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
EP0068719A3 (en) * 1981-06-16 1984-03-28 Takeda Chemical Industries, Ltd. Deoxyribonucleic acids, their production and use
GB2103622B (en) * 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes

Also Published As

Publication number Publication date
DE3279824D1 (en) 1989-08-24
EP0080806B1 (en) 1989-07-19
IE55478B1 (en) 1990-09-26
ATE44765T1 (de) 1989-08-15
IE822543L (en) 1983-04-22
EP0080806A1 (en) 1983-06-08
JPH06165688A (ja) 1994-06-14
CA1338705C (en) 1996-11-12
JP2777622B2 (ja) 1998-07-23
JPH0811735B2 (ja) 1996-02-07
JPS58126815A (ja) 1983-07-28

Similar Documents

Publication Publication Date Title
GR76769B (el)
PT584348E (pt) Vacina genetica para virus da imunodeficiencia
KR890701125A (ko) 무병원성 미생물 및 이의 용도
IL97720A0 (en) Live vaccines
ES500567A0 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
GB8610983D0 (en) Enhancement of antigen immunogenicity
HUT50048A (en) Process for producing streptococcus protein antigen and pharmaceutical compositions comprising same
ES2007720A6 (es) Procedimiento de obtencion de una vacuna a base de flagelo bacterial.
NZ502144A (en) Multi-subtype FIV vaccines
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
EP0498804A4 (en) A method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
IE940698L (en) Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
ATE73349T1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
ATE102650T1 (de) Mutanten des infektioesen bovinen rhinotracheitisvirus, vakzine die sie enthalten, verfahren zu ihrer herstellung und ihrer verwendung.
GB2227936A (en) Vaccine against brucella abortus
EP0636030A4 (en) VACCINE AGAINST THE -I BACTERIAL OXIDE (PASTEURELLIA HAEMOLYTICA).
EP0186368A3 (en) Biological preparations
ATE138269T1 (de) Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
Sela et al. Synthetic approaches to vaccination against cholera toxin.
Rethy Experimental-epidemiological studies on the immunological interactions between live and/or killed virus vaccines applied simultaneously with inactivated monovalent or combined vaccines. Survey of human results achieved between 1960-1978.
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
IT1255037B (it) Procedimento per la preparazione di vaccini basato sulla identificazione di sequenze amminoacidiche dell'antigene simili a sequenze amminoacidiche dell'organismo da immunizzare, e vaccini cosi'ottenibili.
TH6095EX (th) วัคซีนและวิธีเตรียม